摘要
目的探究阿替普酶与尿激酶在急性脑梗死治疗中的临床效果及安全性。方法从该院2013年3月—2019年3月选取92例急性脑梗死患者,将患者随机分成两组,每组46例,一组为观察组,使用阿替普酶进行治疗。一组为对照组,使用尿激酶治疗。对观察组和对照组的治疗效果、日常生活能力与神经缺损情况以及不良反应情况进行观察比较。结果观察组和对照组的治疗有效率分别是89.13%、78.26%,两组数据差异无统计学意义(χ^(2)=1.991,P>0.05)。治疗后,两组组间比较,日常生活能力(ADL)评分、神经功能缺损评分(NIHSS)评分差异无统计学意义(P>0.05)。组内比较,两组治疗后的ADL评分,明显高于治疗前,NIHSS评分明显低于治疗前,差异有统计学意义(P<0.05)。观察组与对照组的不良反应发生率比较,差异无统计学意义(χ^(2)=1.795,P>0.05)。结论阿替普酶与尿激酶对急性脑梗死的治疗效果相当,均能够有效改善患者的神经功能和生活能力,并且不良反应少,安全性较好。
Objective To explore the clinical effects and safety of alteplase and urokinase in the treatment of acute cerebral infarction.Methods From March 2013 to March 2019,92 patients with acute cerebral infarction were selected from the hospital,and the patients were randomly divided into two groups,46 cases in each group,one group was the observation group and treated with alteplase.One group was the control group and was treated with urokinase.Observed and compared the treatment effects,activities of daily living,nerve defects,and adverse reactions between the observation group and the control group.Results The effective rates of treatment in the observation group and control group were 89.13%and 78.26%,respectively.There was no significant difference between the two groups of data(χ^(2)=1.991,P>0.05).After treatment,there was no statistically significant difference in the ability of daily living(ADL)score and neurological impairment score(NIHSS)score between the two groups(P>0.05).Compared within the group,the ADL scores of the two groups after treatment were significantly higher than those before treatment,and the NIHSS score was significantly lower than before treatment,the difference was statistically significant(P<0.05).The incidence of adverse reactions between the observation group and the control group was not statistically significant difference(χ^(2)=1.795,P>0.05).Conclusion Alteplase and urokinase have the same therapeutic effect on acute cerebral infarction.Both can effectively improve the patient's neurological function and living ability,with few adverse reactions and good safety.
作者
张勇
王蕾
姜明杰
李越
侯静
ZHANG Yong;WANG Lei;JIANG Ming-jie;LI Yue;HOU Jing(Department of Neurology,PLA 92493 Army Hospital,Huludao,Liaoning Province,125000 China)
出处
《世界复合医学》
2021年第2期182-184,共3页
World Journal of Complex Medicine
关键词
阿替普酶
尿激酶
急性脑梗死
临床效果
安全性
Alteplase
Urokinase
Acute cerebral infarction
Clinical effect
Safety
